Literature DB >> 4425764

Absorption, metabolism and distribution of (14C)-O-methyldopa and (14C)-L-dopa after oral administration to rats.

L Rivera-Calimlim.   

Abstract

1 The absorption, tissue distribution, and metabolism of [(14)C]-O-methyldopa were compared with those of [(14)C]-L-DOPA after oral administration to rats.2 Total radioactivity in the plasma and brain of rats treated with [(14)C]-O-methyldopa was significantly higher (2 fold and 30-50 fold, respectively) than that of rats treated with [(14)C]-L-DOPA.3 Total radioactivity in the gut washings and intestinal tissue 2 h after oral administration was significantly higher in rats treated with [(14)C]-L-DOPA than in rats treated with [(14)C]-O-methyldopa. The reverse was observed in the stomach tissues.4 Peripheral metabolism of [(14)C]-O-methyldopa was much lower than that of [(14)C]-L-DOPA; the major metabolite of [(14)C]-O-methyldopa in the plasma is L-DOPA, whereas L-DOPA is mainly metabolized to phenylcarboxylic acids.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4425764      PMCID: PMC1776645          DOI: 10.1111/j.1476-5381.1974.tb08570.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  10 in total

1.  3-O-Methyldopa, L-dopa, and trihexyphenidyl in the treatment of Parkinson's disease.

Authors:  M D Muenter; R P Dinapoli; N S Sharpless; G M Tyce
Journal:  Mayo Clin Proc       Date:  1973-03       Impact factor: 7.616

2.  Parkinsonism treated with 3-O-methyldopa.

Authors:  D B Calne; J L Reid; S D Vakil
Journal:  Clin Pharmacol Ther       Date:  1973 May-Jun       Impact factor: 6.875

3.  L-3,4-dihydroxyphenylalanine metabolism by the gut in vitro.

Authors:  L Rivera-Calimlim; J P Morgan; C A Dujovne; J R Bianchine; L Lasagna
Journal:  Biochem Pharmacol       Date:  1971-11       Impact factor: 5.858

4.  Dopa and 3-O-methyldopa in cerebrospinal fluid of Parkinsonism patients during treatment with oral L-dopa.

Authors:  N S Sharpless; D S McCann
Journal:  Clin Chim Acta       Date:  1971-01       Impact factor: 3.786

5.  Metabolism and absorption of L-3,4 dihydroxyphenylalanine in patients with Parkinson's disease.

Authors:  J R Bianchine; L R Calimlim; J P Morgan; C A Dujuvne; L Lasagna
Journal:  Ann N Y Acad Sci       Date:  1971-07-06       Impact factor: 5.691

6.  [Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa?].

Authors:  G Gauthier; J de Ajuriaguerra; F Geissbuhler; B Simona; J Constantinidis; G Yanniotis; M Krassoievitch; J J Eisenring; R Tissot
Journal:  Presse Med       Date:  1971-01-16       Impact factor: 1.228

7.  Absorption and metabolism of L-dopa by the human stomach.

Authors:  L Rivera-Calimlim; C A Dujovne; J P Morgan; L Lasagna; J R Bianchine
Journal:  Eur J Clin Invest       Date:  1971-05       Impact factor: 4.686

8.  The metabolism of L-3-O-methyldopa, a precursor of dopa in man.

Authors:  I Kuruma; G Bartholini; R Tissot; A Pletscher
Journal:  Clin Pharmacol Ther       Date:  1971 Jul-Aug       Impact factor: 6.875

9.  "On-off" phenomena related to high plasma levodopa.

Authors:  L E Claveria; D B Calne; J G Allen
Journal:  Br Med J       Date:  1973-06-16

10.  Distribution and metabolism of L-3-O-methyldopa in rats.

Authors:  G Bartholini; I Kuruma; A Pletscher
Journal:  Br J Pharmacol       Date:  1970-11       Impact factor: 8.739

  10 in total
  2 in total

1.  3-O-methyl-6-[18F]fluoro-L-DOPA and its evaluation in brain tumour imaging.

Authors:  B Beuthien-Baumann; J Bredow; W Burchert; F Füchtner; R Bergmann; H-D Alheit; G Reiss; R Hliscs; R Steinmeier; W-G Franke; B Johannsen; J Kotzerke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-24       Impact factor: 9.236

2.  Alternative pathway for dopamine production by acetogenic gut bacteria that O-Demethylate 3-Methoxytyramine, a metabolite of catechol O-Methyltransferase.

Authors:  Barry E Rich; Jayme C Jackson; Lizett Ortiz de Ora; Zane G Long; Kylie S Uyeda; Elizabeth N Bess
Journal:  J Appl Microbiol       Date:  2022-06-29       Impact factor: 4.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.